Axon Enterprise (NASDAQ:AXON) Posts Quarterly Earnings Results, Beats Expectations By $0.58 EPS

Key Points

• Axon Enterprise reported earnings of $0.85 per share, significantly missing analysts' estimates of $1.54 by $0.69.
• Despite the earnings miss, Axon stock rose 0.3% to $744.88 following the earnings release, with a market capitalization of $57.99 billion.
• Multiple equity analysts have expressed positive forecasts, raising target prices for Axon stock, reflecting a consensus average price target of $772.08 with a rating of "Moderate Buy."

Axon Enterprise (NASDAQ:AXON - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58, Briefing.com reports. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm's revenue was up 32.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.20 EPS. Axon Enterprise updated its FY 2025 guidance to EPS.

Axon Enterprise Trading Up 0.3%

Axon Enterprise stock opened at $744.88 on Tuesday. The business has a 50 day moving average price of $764.81 and a two-hundred day moving average price of $658.28. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The stock has a market cap of $57.99 billion, a price-to-earnings ratio of 179.92, a price-to-earnings-growth ratio of 82.76 and a beta of 1.36. Axon Enterprise has a 12 month low of $279.02 and a 12 month high of $830.21.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 3,400 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the transaction, the chief financial officer owned 131,833 shares of the company's stock, valued at $92,283,100. This represents a 2.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the transaction, the director directly owned 17,740 shares of the company's stock, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,642 shares of company stock worth $25,090,528. 5.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $480,000. Empowered Funds LLC raised its stake in shares of Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company's stock valued at $1,067,000 after purchasing an additional 157 shares during the period. NewEdge Advisors LLC raised its stake in shares of Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company's stock valued at $1,207,000 after purchasing an additional 668 shares during the period. Finally, Woodline Partners LP grew its holdings in shares of Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company's stock valued at $3,646,000 after acquiring an additional 2,003 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AXON has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. Needham & Company LLC upped their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the stock an "overweight" rating in a research note on Friday, July 11th. Wolfe Research began coverage on Axon Enterprise in a research note on Monday, July 7th. They set an "outperform" rating for the company. Finally, UBS Group began coverage on Axon Enterprise in a research report on Wednesday, July 16th. They set a "neutral" rating and a $820.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $772.08.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.